öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºº«Î°
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º65

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£º
Ö°³Æ£º¸±Ö÷ÈÎҽʦ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÄÚ¿Æѧ
Ñо¿ÁìÓò£º ºôÎü¼²²¡µÄÁÙ´²¹¤×÷ºÍ»ù´¡Ñо¿
Ñо¿ÁìÓò£º ºôÎü¼²²¡µÄÁÙ´²¹¤×÷ºÍ»ù´¡Ñо¿ [ÊÕÆð]




¸öÈ˼òÊö :
º«Î°£¬²©Ê¿£¬¸±Ö÷ÈÎҽʦ£¬Ë¶Ê¿Éúµ¼Ê¦¡£¡£ÏÖÈÎÖ°ÓÚÇൺÊÐÊÐÁ¢Ò½Ôº¶«ÔººôÎüÄÚ¶þ¿ÆÖ÷ÈΡ£2006Äê±ÏÒµÓÚ¸´µ©´óѧ£¬»ñºôÎü²¡Ñ§²©Ê¿Ñ§Î»¡£2013Ä기ÃÀ¹úµÂ¿ËÈø˹ÖÝ´óѧ£¨University of Texas£©µÄ°²µÂÉ­Ö×ÁöÖÐÐÄ£¨MD Anderson Cancer Center£©´Óʲ©Ê¿ºóÑо¿¡£2008Ä굱ѡɽ¶«Ê¡ÇàÄê¸ÚλÄÜÊÖ£»2009Äê»ñÇൺÊÐÇàÄê¿Æ¼¼½±£»2013Ä굱ѡÇൺÊÐÎÀÉúϵͳ°Î¼âÈ˲Å£¬2016Ä꣬µ±Ñ¡ÇൺÊÐÓÅÐãѧ¿Æ´øÍ·È˼ƻ®£¬2017Ä굱ѡÇൺÊаμâÈ˲Å¡£ÖйúҽʦЭ»áºôÎüҽʦ·Ö»áÖÐÇàÄêίԱ»á³£Î¯£¬É½¶«Ê¡Ò½Ê¦Ð­»áºôÎüҽʦ·Ö»áÖÐÇàÄêίԱ»á¸±Ö÷ί£¬É½¶«Ê¡Ò½Ñ§»áºôÎüѧ»áÇàÄêίԱ»áίԱ¡¢Ïø´­Ñ§×éίԱ£¬ÇൺÊÐҽѧ»á¿ÆÆÕ·Ö»áÖ÷ί£¬ÇൺÊÐҽѧ»áºôÎü·Ö»áÇàÄêίԱ»á¸±Ö÷ί¡¢Ñ̲ݲ¡Ñ§×é×鳤¡£ÔÚºôÎü¼²²¡µÄÁÙ´²ºÍ»ù´¡Ñо¿£¬Ï¸°û·Ö×ÓÉúÎïѧ¡¢ÒÅ´«Ñ§¡¢Ö×ÁöÉúÎïѧµÈѧ¿ÆÓÐÒ»¶¨ÔìÒ裬µÃµ½Á˹úÄÚÍâͬÐеÄÈÏ¿É£¬µ£Èζ౾SCIÔÓÖ¾µÄÉó¸åÈË£¬»ñɽ¶«Ê¡¿Æ¼¼½ø²½½±ºÍÇൺÊпƼ¼½ø²½½±¶àÏî¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿
×÷Ϊ¿ÎÌ⸺ÔðÈË»ñµÃ¹ú¼Ò×ÔÈ»»ù½ðÏîÄ¿¡¢ÇൺÊпƼ¼¾ÖºÍÇൺÊÐÊÐÄÏÇø¿Æ¼¼¾ÖÏîÄ¿£º
1. ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¬¡°·ÊÅÖÏø´­Muc5ac¸ß·ÖÃÚºÍMunc18bÉϵ÷µÄ¹Øϵ¼°»úÖÆ¡±£¬ÏîÄ¿¸ºÔðÈË¡£2. ÇൺÊпƼ¼¾ÖÏîÄ¿£¬¡°Treg/Th17ʧºâÔÚ·ÊÅÖÏø´­ÐγÉÖеÄ×÷Óü°Æä»úÖÆ¡±£¬¿ÎÌ⸺ÔðÈË¡£3. ÇൺÊÐÊÐÄÏÇø¿Æ¼¼ÏîÄ¿£¬¡°Ïø´­»¼ÕßÆøµÀÑ×Ö¢¼à²â·½·¨µÄÑо¿¡±£¬ÏîÄ¿¸ºÔðÈË¡£4. ÇൺÊÐÎÀÉú¾Ö¿ÎÌ⣬¡°·ÊÅÖÏø´­Ð¡ÊóÕ³µ°°×¸ß·ÖÃÚÓëSMµ°°×µÄ¹Øϵ¡±£¬ÏîÄ¿¸ºÔðÈË¡£5. ÇൺÊС°ÓÅÐãѧ¿Æ´øÍ·ÈË¡±ÏîÄ¿£¬ÏîÄ¿¸ºÔðÈË¡£
´ú±íÎÄÕ£¨* ͨѶ×÷Õߣ©
1) Han W, Li J, Tang H, Sun L*.Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level. Biochem Biophys Res Commun, 2017, 484(2): 396-402.
2) Sun L, Xue W, Li J, Zhou Z, Han W*. Palm dermatoglyphs and interleukin-4 receptor polymorphisms in asthma. Biomed Rep, 2017, 6(1): 21-26.
3) Xue W, Han W*, Zhou ZS. ADAM33 polymorphisms are associated with asthma and a distinctive palm dermatoglyphic pattern. Mol Med Rep, 2013, 8(6):1795-800.
4) Tang HP, Sun LX, Han W*. Endothelial cells on the proliferation and expression of intercellular adhesion molecule 1 and interleukin 8 of vascular smooth muscle cells. Genet Mol Res, 2013, 12(4): 4363-70.
5) Àî¾ý£¬ÍõÀöϼ£¬ÌÆ»ªÆ½£¬º«Î°*. ÐÁ·¥ËûÍ¡¶Ô·ÊÅÖÏø´­Ð¡ÊóÆøµÀÑ×Ö¢µÄ×÷Óü°Æä»úÖÆ. ÖйúÏÖ´úҽѧÔÓÖ¾£¬2016, 26(11): 7-11.